Objectives and Expected Results >
Download Program - updated November 17th (pdf)
Wednesday, March 24, 2010
14:00 – 18:00 Registration at the International Conference Centre (CICG)
16:30 – 17:00 Welcome address
Ezio Giacobini and Gabriel Gold, Organizers
René Rizzoli, Head of the Department of Rehabilitation and Geriatrics, Geneva University Hospitals
Bernard Gruson, General Director, Geneva University Hospitals
Jean-Louis Carpentier, Dean, Faculty of Medicine, University of Geneva
J. Kevin Dorsey, Dean, Southern Illinois University School of Medicine, Springfield
Minister of Health of the Republic and Swiss Canton of Geneva 17:00 – 18:00
Opening Lecture:
Richard Frackowiak (Lausanne, Switzerland)
London Taxi Drivers, Hippocampus and Alzheimer Disease 18:00 – 19:30
Welcome Reception: CICG
Thursday, March 25, 2010
Room A
08:15 – 08:35 State of the art lecture:
Serge Gauthier (Montreal, Canada)
Why so few drugs for AD? The question
Why so Few Drugs for AD?
08:35 – 08:55 Robert Becker (South Freeport, USA)
Why so few AD drugs? Could methods be failing drugs?
08:55 – 09:15 Cristina Sampaio (Lisbon, Portugal)
Regulatory view point
09:15 – 09:35 Lon Schneider (Los Angeles, USA)
The clinical trial: wrong target or wrong design?
09:35 – 09:55 Eric Siemers (Indianapolis, USA)
The drug company viewpoint
09:55 – 10:25 Break
10:25 – 10:45 State of the art lecture: Roger Nitsch (Zurich, Switzerland)
Immunization: the future of AD therapy
The Culprits: Monomers, Dimers, Trimers and Other Oligomers
10:45 – 11:05 Karen Ashe (Minneapolis, USA)
Multiple mechanisms of memory loss in Alzheimer disease: implications for cures
11:05 – 11:25 Stephen Strittmatter (New Haven, USA)
Is the prion protein PrP a receptor for A-beta oligomers?
11:25 – 11:45 Nibaldo Inestrosa (Santiago, Chile)
Amyloid beta oligomers at brain synapses
11:45 – 12:05 William Klein (Chicago, USA)
Synaptoxic A-beta oligomers (ADDLs): A molecular basis for the cause, diagnosis, and treatment of Alzheimer disease
12:05 – 13:30 Lunch
13:30 – 15:10 From Bench to Bedside: The Multiple Actions of beta-Amyloid in Alzheimer Disease
(mini-symposium supported by Elan)
15:10 – 15:40 Break
Active and Passive Immunization
15:40 – 16:00
Dale Schenk (South San Francisco, USA)
A-beta immunotherapy for the treatment of Alzheimer disease
16:00 – 16:20
Ronald DeMattos (Indianapolis, USA)
A-beta immunotherapy: tailoring specific biomarkers for clinical development
16:20 – 16:40
Bengt Winblad (Stockholm, Sweden)
Immunotherapy studies in Alzheimer disease – present experiences
16:40 – 17:00
Ronald Black (Collegeville, USA)
Progress in the immunotherapeutic approach to Alzheimer disease
17:20 – 19:00
Reception with poster viewing and discussion
Thursday, March 25, 2010
Room B
08:15 – 08:35
State of the art lecture: Jaakov Stern (New York, USA)
Brain reserve impact on AD
Imaging of the Brain: Testing Drug Effects
08:35 – 08.55
William Klunk (Pittsburgh, USA)
Amyloid imaging: strengths and weaknesses in drug development
08:55 – 09:15
Hilkka Soininen (Kuopio, Finland)
MRI imaging of the brain: testing drug effects
09:15 – 09:35
William Jagust (Berkeley, USA)
Imaging in drug development: It’s not just amyloid
09:35 – 09:55
Agneta Nordberg (Stockholm, Sweden)
Amyloid imaging in the evaluation of new drug therapy in AD
09:55 – 10:25 Break
10:25 – 10:45 State of the art lecture:
Renaud Du Pasquier (Lausanne, Switzerland)
Diagnosis and treatment of cognitive disorders in HIV-infected patients
Emerging Novel Therapeutic Targets I
10:45 – 11:05
Abraham Fisher (Ness Ziona, Israel)
Muscarinic agonists: A powerful weapon in the anti-AD arsenal
11:05 – 11:25
Achim Schneeberger (Vienna, Austria)
AFFITOPE Alzheimer vaccines
11:25 – 11:45
Israel Hanin (Tucson, USA)
A-beta anti-aggregants
11:45 – 12:05
Gerhard Koenig (Watertown, USA)
Nicotinic compounds for cognitive deficits
(session partially supported by Affiris GmbH, Austria ; Cornelli Consulting, Italy ; EnVivo Pharmaceuticals, USA)
12:05 – 13:30 Lunch
13:30 – 13:50 State of the art lecture:
François Herrmann (Geneva, Switzerland)
Do intelligent and educated people live longer?
Focusing on Early Diagnosis and Treatment of Alzheimer Disease
13:50 – 14:10
Steven DeKosky (Charlottesville, USA)
Amyloid burden in normal and MCI subjects
14:10 – 14:30
Jean-Marc Orgogozo (Bordeaux, France)
Prodromal Alzheimer disease
14:30 – 14:50
Christoph Hock (Zurich, Switzerland)
Immunological features of healthy aging, MCI and Alzheimer disease
14:50 – 15:10
John Morris (St. Louis, USA)
Non-demented aging and preclinical Alzheimer disease
15:10 – 15:40 Break
15:40 – 16:00 State of the art lecture:
Dina Zekry (Geneva, Switzerland)
Oxidative stress and Alzheimer disease
Prevention of AD
16:00 – 16:20
Laura Fratiglioni (Stockholm, Sweden)
Risk factors and prevention
16:20 – 16:40
Miia Kivipelto (Stockholm, Sweden)
Prevention of AD: is it possible? Nordic multi-domain intervention studies
16:40 –17:00
Bruno Vellas (Toulouse, France)
The GuidAge study: new results
17:00 – 17:20
Patrizia Mecocci (Perugia, Italy)
Mitochondria: targets of preventive therapy
17:20 – 19:00
Reception with poster viewing and discussion
Friday, March 26, 2010
Room A
Advances in Neuroimaging for Alzheimer Disease
Chairs: Mike Weiner and Samuel Svensson
08:15 – 08:20
Introduction
08:20 – 08:40
Michael Weiner (San Francisco, USA)
Use of biomarkers in AD treatment trials: The Alzheimer disease neuroimaging initiative
08:40 – 09:00
Nick Fox (London, UK)
4D MRI: measuring change for early detection and monitoring of progression09:00 – 09:20Simon Lovestone (London, UK)
Multimodal markers of disease – imaging and plasma results from the AddNeuroMed study09:20 – 09:40
Eric Reiman (Phoenix, USA)
(18F)AZD4694 Amyloid PET studies in pre-symptomatic and Alzheimer disease patients
09:40 – 09:55
Discussion
(mini-symposium supported by AstraZeneca)
09:55 – 10:25 Break
10:25 – 12:05 Developing the Next Generation of Treatment
(mini-symposium supported by Pfizer)
12:05 – 13:30 Lunch
13:30 – 15:10
Treatment of Alzheimer’s Disease – Short Term Benefits and Beyond
(mini-symposium supported by Lundbeck, A/S)
15:10 – 15:40 Break
Emerging Hypotheses in Cholinesterase Inhibition: Targeted Activity for Optimal Effects
Chair: Lutz Frölich
15:40 – 15:45
Chairman’s introduction
15:45 – 16:10
Lutz Frölich (Mannheim, Germany)
Ambitious dementia treatment with high doses of
cholinesterase inhibitors
16:10 – 16:35
Roger Bullock (Swindon, UK)
Long-term effects of cholinesterase inhibition
– the good, the bad, and the ugly!
16:35 – 17:00
Sultan Darvesh (Halifax, Canada)
Possible mechanisms underlying effects of BuChE – emerging hypotheses
to spark future research
17:00 – 17:15
Questions from the audience
17:15 – 17:20
Chairman’s conclusions
(mini-symposium supported by Novartis)
Friday, March 26, 2010
Room B
08:15 – 08:35 State of the art lecture:
Giancarlo Pepeu (Florence, Italy)
The cholinergic system still exists
The Cholinergic System Still Exists08:35 – 08:55
Elliott Mufson (Chicago, USA)
The cholinergic system in AD: shifts from survival to death
08:55 – 09:15
Claudio Cuello (Montreal, Canada)
The cholinergic system is the most vulnerable to Alzheimer pathology
09:15 – 09:35
Antonio Cattaneo (Pisa, Italy)
How to rescue the cholinergic system with NGF
09:35 – 09:55
Maria Eriksdotter Jönhagen (Stockholm, Sweden)
Therapy of AD with NGF
09:55 – 10:25 Break
10:25 – 10:45 State of the art lecture:
Kaj Blennow (Mölndal, Sweden)
Predictive biomarkers of early AD
Preclinical Models of AD and Neural Stem Cells
10:45 – 11:05
Manfred Windisch (Graz, Austria)
Animal models of Alzheimer disease – their predictive value for drug development
11:05 – 11:25
Kiminobu Sugaya (Orlando, USA)
Stem cells for AD treatment
11:25 – 11:45
Greg Brewer (Springfield, USA)
Reversing epigenetic aging in cell models of AD
11:45 – 12:05
Amelia Marutle (Stockholm. Sweden)
Stimulating regenerative mechanisms in Alzheimer disease
(session partially supported by JSW-Lifesciences GmbH, Austria)
12:05 – 13:30 Lunch
13:30 – 13:50 State of the art lecture:
Rudolf Tanzi (Charlestown, USA)
How can we develop drugs for 32 AD-associated genes?
Cerebrovascular Pathology: Cognitive Consequences and Preventive Strategies
13:50 – 14:10
Gabriel Gold (Geneva, Switzerland)
Mixed dementia: what have we learned from neuropathology?
14:10 – 14:30
Philip Scheltens (Amsterdam, The Netherlands)
Subcortical ischemic vascular disease: what have we learned from MRI studies?
14:30 – 14:50
Amos Korczyn (Ramat Aviv, Israel)
Vascular pathology and Non-AD degenerative dementias
14:50 – 15:10
Ingmar Skoog (Göteborg, Sweden)
Subcortical ischemic vascular disease: A target for prevention and treatment in dementia
disorders
15:10 – 15:40 Break
15:40 – 16:00
State of the art lecture: Rodger Elble (Springfield, USA)
Cerebrospinal fluid drainage in the treatment of dementia
Emerging Novel Therapeutic Targets II
16:00 – 16:20
Suzanne Craft (Washington, USA)
Intranasal insulin improves cognition and modulates beta-amyloid in early AD
16:20 – 16:40
Harald Hampel (Frankfurt, Germany)
A clinical trial with lithium for the treatment of AD
16:40 – 17:00
Andy Protter (San Francisco, USA)
Preclinical pharmacology of Dimebon: A new experimental drug for neurodegenerative diseases
17:00 – 17:20
Beka Solomon (Ramat Aviv, Israel)
A new target for AD immunotherapy: Beta secretase
(Session partially supported by Medivation, USA)
Saturday, March 27, 2010Room A
08:15 – 08:35 State of the art lecture:
Constantin Bouras (Geneva, Switzerland)
The brain of the centenarians
Moving to TAU: An Obligatory Step Towards a Disease-Modifying Treatment in AD
Chairs: Khalid Iqbal and Panteleimon Giannakopoulos
08:35 – 08.55
Panteleimon Giannakopoulos (Geneva, Switzerland)
The contribution of tau-related pathology in AD: what we really know?
08:55 – 09:15
Khalid Iqbal (Staten Island, USA)
From tangles to tau protein
09:15 – 09:35
Eckhard Mandelkow (Hamburg, Germany)
Tau aggregation inhibitors in AD
09:35 – 09:55
Karen Duff (New York, USA)
Pathogenic mechanisms and therapeutic approaches for the tauopathies
09:55 – 10:25 Break
10:25 – 10:45 State of the art lecture:
John Breitner (Seattle, USA)
Do non-steroidal anti-inflammatory drugs prevent Alzheimer disease?
Non Alzheimer Disease Dementias: Diagnostic Issues and Treatment
10:45 – 11:05
Bruno Dubois, (Paris, France)
New diagnostic criteria for Parkinson’s disease dementi
11:05 – 11:25
Ian McKeith (Newcastle, UK)
Improving diagnosis in dementia with Lewy bodies (DLB)
11:25 – 11:45
Philippe Robert (Nice, France)
Treating early behavioral and psychological symptoms of dementias
11:45 – 12:05
Roberto Bernabei (Rome, Italy)
Dementia and multimorbidity: importance of comprehensive assessment and treatment
12:05 – 13:30 Lunch
13:30 – 13:50 State of the art lecture:
René Rizzoli (Geneva, Switzerland)
Vitamin D and cognitive functions
Emerging Novel Therapeutic Targets III
13:50 – 14:10
Michael Murphy (Beverly Hills, USA)
Coming full circle – Refined patient phenotypes in disease modification therapy
14:10 – 14:30
Mene Pangalos (Collegeville, USA)
Disease modifying therapies for the treatment of AD
14:30 – 14:50 TBA
14:50 – 15:10 TBA
(session partially supported by Worldwide Clinical Trials, USA; Wyeth Pharmaceuticals, USA)
15:10 – 15:40 Closing remarks
19:00 – 22:30 Speakers dinner (by invitation)
Saturday, March 27, 2010
Room B
08:15 – 08:35 State of the art lecture:
Ezio Giacobini (Geneva, Switzerland)
Why so few drugs for AD? The answer
Oral Communications I
Chairs:
08:35 – 09:55 TBA
09:55 – 10:25 Break
Oral Communications II
10:25 – 10:40
Vic Ramkumar (Springfield, USA)
Protective role of adenosine A1 receptor against beta-amyloid neurotoxicity
10:40 – 10:55
Lawrence Friedhoff (New York, USA)
Phenserine clinical trial
10:55 – 11:10
Ildiko Szanto (Geneva, Switzerland)
Aging related pathologies and oxidative stress
11:10 – 11:25
Amy Arai (Springfield, USA)
Modification of synaptic transmission and plasticity in AD-transgenic mice
11:25 – 11:40 TBA
11:40 – 11:55 TBA
11:55 – 12:05 General discussion
12:05 – 13:30 Lunch
13:30 – 13:50
State of the art lecture: Ulrich Vischer (Geneva, Switzerland)
Diabetes, the metabolic syndrome and Alzheimer disease
Oral Communications III
Chairs:
13:50 – 15:10 TBA
15:10 – 15:40 Closing remarks
19:00 – 22:30 Speakers dinner (by invitation)